Abstract
Background Covid-19 disease is pandemic in more than 85% of the countries in the world, with about 10 million cases and 0.5 million deaths as on July 2, 2020. In India reporting of the first case was on January 30, 2020, and to prevent rapid community spread of the disease nationwide lockdown phase was imposed from March 25- June 1, 2020. Our objective was to assess various epidemiological measures during the lockdown phase.
Methods We used daily reporting of confirmed cases by the Ministry of Health and Family Welfare, Government of India during the period March 19-June 1, 2020. Using statistical packages STATA and R-packages, we fitted three statistical distributions (Gamma, Weibull and Log-normal) to the daily recorded new cases. We estimated daily incidence rate and death rate per million population, generation time and Basic Reproduction numbers.
Results During the lockdown phase, the daily per cent increase in the cumulative number of cases showed negative exponential growth with 0.022 as an instantaneous rate of decrease. The average incidence rate with a 95% confidence interval (CI) was 1.84 (1.43-2.25). Day specific incidence rate per million (revealed the exponential pattern with 0.069 as the instantaneous rate of increase per day, which accounted for the doubling time of the disease (10 days; 95% CI: 9.25-10.93). Case fatality rate (2.92%; 95% CI: 2.82% −3.02%) and overall death rate was 1.14 (95% CI: 0.87-1.41) per million. were abysmally low. Statistical distribution fitting of new cases found to be satisfactory with Gamma distribution. Basic reproduction numbers 1.83 (95% CI: 1.82-1.83) was less.
Conclusion In India, with a population density of about 450 per Km2, the virulent of COVID-19 transmission was interrupted significantly with 70 days lockdown during the early transmission stage. We observed a considerable decline in all the epidemiological indices compared to the corresponding indices recorded during the same period in the severely affected countries.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
It is not a clinical trial
Funding Statement
This study did not have any financial support
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is on the epidemiological profile of COVID-19 disease in India based on empirical data available in the public domain.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos